Showing results (61-70 of 85) with videos related to

Sort By:
Pageof 9
Open Forum Infectious Diseases|September 29, 2025
Ethnic Disparities in Extrahepatic Manifestations Among People With HCV Infection: A Population-Based Study in British ColumbiaDahn Jeong, Stanley Wong, Héctor A Velásquez García, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|July 13, 2016
Safety and Effectiveness of Direct-Acting Antiviral Agents for Treatment of Patients With Chronic Hepatitis C Virus Infection and CirrhosisRaoel Maan, Marjolein van Tilborg, Katja Deterding, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|September 25, 2021
Novel variant in glycophorin c gene protects against ribavirin-induced anemia during chronic hepatitis C treatmentJennifer J Lin, Catrina M Loucks, Jessica N Trueman, et al.
Advances in Therapy|May 11, 2022
Safety and Effectiveness Using 8 Weeks of Glecaprevir/Pibrentasvir in HCV-Infected Treatment-Naïve Patients with Compensated Cirrhosis: The CREST StudyMarkus Cornberg, Adriana Ahumada, Alessio Aghemo, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|May 26, 2020
Global real-world evidence of sofosbuvir/velpatasvir as simple, effective HCV treatment: Analysis of 5552 patients from 12 cohortsAlessandra Mangia, Scott Milligan, Mandana Khalili, et al.
Canadian Liver Journal|August 22, 2022
The Z-Profile Study: a multicenter, retrospective cohort study to assess the real-world use and effectiveness of elbasvir/grazoprevir in Canadian adult patients with chronic hepatitis CEdward Tam, Julie Tremblay, Chris Fraser, et al.
Open Forum Infectious Diseases|December 12, 2025
Impact of COVID-19 Pandemic on Testing for Hepatitis B in British Columbia, Canada: An Interrupted Time Series AnalysisRichard L Morrow, Jean D Makuza, Dahn Jeong, et al.
Viruses|November 24, 2022
Global Real-World Evidence of Sofosbuvir/Velpatasvir as a Highly Effective Treatment and Elimination Tool in People with Hepatitis C Infection Experiencing Mental Health DisordersHeiner Wedemeyer, Vito Di Marco, Montserrat Garcia-Retortillo, et al.
Canadian Liver Journal|August 22, 2022
Current considerations for clinical management and care of non-alcoholic fatty liver disease: Insights from the 1st International Workshop of the Canadian NASH Network (CanNASH)Giada Sebastiani, Keyur Patel, Vlad Ratziu, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|May 24, 2017
Ledipasvir-Sofosbuvir Plus Ribavirin in Treatment-Naive Patients With Hepatitis C Virus Genotype 3 Infection: An Open-Label StudyJordan J Feld, Alnoor Ramji, Stephen D Shafran, et al.
Pageof 9